Resonance Health attended and exhibited at the American Association for the Study of Liver Disease (AASLD) conference in Boston on the 7-11 November.

This provided an ideal opportunity to launch the company's new HepaFat-Scan product for assessing liver fat using MRI, which has been cleared for marketing by the FDA. The conference is the largest meeting of liver specialists held anywhere in the world with over 10,000 attendees. Feedback was positive about the potential use of HepaFat-Scan to improve the diagnosis and management of patients with fatty liver disease. It’s validation across multiple MRI scanner makes and models makes it ideal for use in clinical studies involving multiple hospitals.